Ghanem A - Search Results

1

The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Abuelazm M, Ghanem A, Awad AK, Farahat RA, Labieb F, Katamesh BE, Abdelazeem B. Abuelazm M, et al. Among authors: ghanem a. Clin Drug Investig. 2022 Dec;42(12):1031-1047. doi: 10.1007/s40261-022-01213-y. Epub 2022 Oct 31. Clin Drug Investig. 2022. PMID: 36315350 Free PMC article.

2

The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis.

Abuelazm M, Ghanem A, Mahmoud A, Brakat AM, Elzeftawy MA, Mamdouh Fayoud A, Awad AK, Abdelazeem B. Abuelazm M, et al. Among authors: ghanem a. Clin Rheumatol. 2023 Jun;42(6):1503-1520. doi: 10.1007/s10067-023-06519-6. Epub 2023 Feb 16. Clin Rheumatol. 2023. PMID: 36792848 Free PMC article. Review.

3

Reno-protective effects of perioperative dexmedetomidine in kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.

Abuelazm MT, Ghanem A, Johanis A, Mahmoud A, Hassan AR, Katamesh BE, Amin MA, Abdelazeem B. Abuelazm MT, et al. Among authors: ghanem a. Int Urol Nephrol. 2023 Oct;55(10):2545-2556. doi: 10.1007/s11255-023-03568-3. Epub 2023 Mar 30. Int Urol Nephrol. 2023. PMID: 36997837 Free PMC article. Review.

4

Defibrillation strategies for refractory ventricular fibrillation out-of-hospital cardiac arrest: A systematic review and network meta-analysis.

Abuelazm MT, Ghanem A, Katamesh BE, Hassan AR, Abdalshafy H, Seri AR, Awad AK, Abdelnabi M, Abdelazeem B. Abuelazm MT, et al. Among authors: ghanem a. Ann Noninvasive Electrocardiol. 2023 Sep;28(5):e13075. doi: 10.1111/anec.13075. Epub 2023 Jul 22. Ann Noninvasive Electrocardiol. 2023. PMID: 37482919 Free PMC article. Review.

5

The diagnosis, genetic alternation, and treatment of the primary pleomorphic liposarcoma of the femur in a rare age: Case report and literature review.

Wu H, Ghanem AK, Abbas KS, Abdalshafy H, Abdelazeem B, Wang H, Zhang J, Zhang C. Wu H, et al. Heliyon. 2024 Aug 29;10(17):e36953. doi: 10.1016/j.heliyon.2024.e36953. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39296074 Free PMC article.

6

Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.

7

COVID-19 IgG/IgM antibody testing in Los Angeles County, California.

Ahmad K, Rezvanizadeh V, Dahal S, Kinninger A, Ghanem AK, Lakshmanan S, Hamal S, Flores F, Dailing C, Roy SK, Budoff MJ. Ahmad K, et al. Among authors: ghanem ak. Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):457-459. doi: 10.1007/s10096-020-04111-3. Epub 2020 Nov 25. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33241444 Free PMC article.

8

Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.

Hamidi H, Bagheri M, Benzing T, Krishnan S, Kianoush S, Ichikawa K, Ghanem AK, Javier D, Iskander B, Aldana-Bitar J, Budoff MJ. Hamidi H, et al. Am Heart J. 2024 Dec;278:24-32. doi: 10.1016/j.ahj.2024.08.015. Epub 2024 Aug 24. Am Heart J. 2024. PMID: 39187147

9

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.

10

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

757 results

Search Page

Filters